Following its acquisition of Kyowa Pharmaceutical Industry in 2007, the Indian generics company Lupin has made its second foray into the Japanese generics market by agreeing to acquire up to 100% of the outstanding shares of I’rom Pharmaceutical, a manufacturer of generic injectables. With the acquisition, Lupin will gain a significant presence in Japan’s growing diagnosis procedure combination (DPC) hospital market. The Japanese government mandates such hospitals to offer low-cost healthcare services.